KR20240147980A - 신경퇴행성 또는 신경계 질환 또는 장애에 대한 과립구-대식세포 집락-자극 인자-기반 치료 - Google Patents
신경퇴행성 또는 신경계 질환 또는 장애에 대한 과립구-대식세포 집락-자극 인자-기반 치료 Download PDFInfo
- Publication number
- KR20240147980A KR20240147980A KR1020247024332A KR20247024332A KR20240147980A KR 20240147980 A KR20240147980 A KR 20240147980A KR 1020247024332 A KR1020247024332 A KR 1020247024332A KR 20247024332 A KR20247024332 A KR 20247024332A KR 20240147980 A KR20240147980 A KR 20240147980A
- Authority
- KR
- South Korea
- Prior art keywords
- csf
- patient
- disease
- expression
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309220P | 2022-02-11 | 2022-02-11 | |
| US63/309,220 | 2022-02-11 | ||
| PCT/US2023/062374 WO2023154855A2 (en) | 2022-02-11 | 2023-02-10 | Granulocyte-macrophage colony-stimulating factor-based treatments for neurodegenerative or neurological diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240147980A true KR20240147980A (ko) | 2024-10-10 |
Family
ID=87565120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247024332A Pending KR20240147980A (ko) | 2022-02-11 | 2023-02-10 | 신경퇴행성 또는 신경계 질환 또는 장애에 대한 과립구-대식세포 집락-자극 인자-기반 치료 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250134959A1 (https=) |
| EP (1) | EP4475874A2 (https=) |
| JP (1) | JP2025508308A (https=) |
| KR (1) | KR20240147980A (https=) |
| CN (1) | CN118660715A (https=) |
| AU (1) | AU2023219770A1 (https=) |
| CA (1) | CA3242855A1 (https=) |
| WO (1) | WO2023154855A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023235795A2 (en) * | 2022-06-01 | 2023-12-07 | Partner Therapeutics, Inc. | Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders |
| WO2025168003A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海市第四人民医院 | 一种治疗神经退行性疾病的药物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785601B2 (en) * | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| JP2023514972A (ja) * | 2020-02-12 | 2023-04-12 | ザ スクリプス リサーチ インスティテュート | 長時間作用型ｇｍ－ｃｓｆおよび使用方法 |
-
2023
- 2023-02-10 AU AU2023219770A patent/AU2023219770A1/en active Pending
- 2023-02-10 JP JP2024542110A patent/JP2025508308A/ja active Pending
- 2023-02-10 EP EP23753693.3A patent/EP4475874A2/en active Pending
- 2023-02-10 US US18/837,235 patent/US20250134959A1/en active Pending
- 2023-02-10 WO PCT/US2023/062374 patent/WO2023154855A2/en not_active Ceased
- 2023-02-10 CA CA3242855A patent/CA3242855A1/en active Pending
- 2023-02-10 KR KR1020247024332A patent/KR20240147980A/ko active Pending
- 2023-02-10 CN CN202380021043.5A patent/CN118660715A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118660715A (zh) | 2024-09-17 |
| WO2023154855A2 (en) | 2023-08-17 |
| CA3242855A1 (en) | 2023-08-17 |
| EP4475874A2 (en) | 2024-12-18 |
| JP2025508308A (ja) | 2025-03-26 |
| AU2023219770A1 (en) | 2024-08-22 |
| WO2023154855A3 (en) | 2023-10-05 |
| US20250134959A1 (en) | 2025-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110461871B (zh) | 白蛋白结合结构域融合蛋白 | |
| ITRM940794A1 (it) | Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 | |
| US10695404B2 (en) | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs | |
| JP7678802B2 (ja) | Ｓｉｇｌｅｃ－９ＥＣＤ融合分子及びその使用方法 | |
| KR20240147980A (ko) | 신경퇴행성 또는 신경계 질환 또는 장애에 대한 과립구-대식세포 집락-자극 인자-기반 치료 | |
| CN103476933A (zh) | 白介素1受体的拮抗剂 | |
| Silverstein et al. | CD36-TSP-HRGP interactions in the regulation of angiogenesis | |
| US20070149439A1 (en) | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo | |
| KR20080060226A (ko) | 신경 질환의 치료 및/또는 예방을 위한 ｓｄｆ-1의 용도 | |
| KR20040008177A (ko) | 신경 사 단백질 세그먼트를 사용하여 세포 사멸을억제하는 방법 | |
| US20170137483A1 (en) | Use of epo-derived peptide fragments for the treatment of inflammatory diseases | |
| EP3917958A1 (en) | Treatment of neurotoxicity and / or cytokine release syndrome | |
| US20240361339A1 (en) | Biomarkers for parkinson's disease | |
| EP1740199B1 (en) | Il6r/il6 chimera for therapy of chemotherapy-induced peripheral neuropathy | |
| JP2007534746A (ja) | 化学療法誘発性ニューロパシーの治療または予防のためのｉｌ−６ | |
| CN108295242A (zh) | 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用 | |
| CA2938366C (en) | New pharmaceutical compositions and their use for the treatment of autoimmune disorders | |
| CN118043672A (zh) | 帕金森病的生物标志物 | |
| WO2023235795A2 (en) | Granulocyte-macrophage colony-stimulating factor-based treatments for pulmonary or respiratory diseases or disorders | |
| AU2011203356B2 (en) | IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy | |
| US20090291887A1 (en) | Proteins of the SDF-1-Family for the Manufacturing of a Medicament | |
| KR20040029968A (ko) | 신경 사 단백질에 대한 항체를 사용하여 세포 사멸을억제하는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |